Friday, 18 Jan 2019

You are here

The RheumNow Week in Review -30 March 2018

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.

  1.  FDA Arthritis Advisory Committee is scheduled to meet on April 23rd to discuss the NDA for Eli Lilly's JAK inhibitor - baricitinib in moderate to severe RA. Discussion will be around risk:benefit assessment, dose selection & the risk of venous thromboembolic events. https://t.co/dQ4AdYZyQx
  2. FDA grants Fast Track designation to nintedanib for Rx of systemic sclerosis with interstitial lung disease, for which there is no approved therapy. Pending are results from SENSCIS study -nintedanib over 52 weeks in SSc-ILD. https://t.co/CdnhvETtCZ 
  3. Although approved by FDA in May 2017, the EMA (CHMP) has rejected abaloparitide for treatment of postmenopausal osteoporosis, citing cardiac concerns, study conduct & its data on non-vertebral fracture prevention. https://t.co/vYE96VkiRY
  4. Large BSRBR study of Serious infections w/ biologics shows SI=5.51 per 100PY for all; tocilizumab was higher vs ETN (HR 1.22; 1.02 to 1.47) & certolizumab lower or equal to ETN. 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%). https://t.co/h5BieShHpH
  5. TB in USA continues to decline, in 2017, there were 9,093 new cases TB = an incidence rate of 2.8 cases per 100,000. TB is 15 times higher among non–U.S.-born persons (compared to U.S.-born persons) https://t.co/Jj30Pv3CFW
  6. Survey of 442 Dutch axial SpA patients finds Hidradenitis suppurativa twice as common (9.1% vs 4.1%) in AxSpA - HS/AxSpA more likely female with higher ASAS & BASDAI scores w/ more dactylitis & enthesitis. https://t.co/yJeyIr5uiM
  7. Analysis of US hospitalizations from 7 states compared 28269 lupus w/ 13269 controls; SLE associated with 33% more postoperative renal complications &  27% greater in-hospital mortality, BUT no higher rate of cardiac complications https://t.co/e40HUEWzmY
  8. UK gen population database shows that statin use in gout patients was associated with a 16% lower risk of all-cause mortality (HR=0.84) & 7.7 fewer deaths per 1,000 PY; moreso in those without prior CV disease https://t.co/ZFpvSelo4d
  9. IL-37 is elevated in active adult-onset Still's disease and may be a biomarker of AOSD activity. IL-37 correlates with systemic score, IL-1β, IL-18, and IL-10. IL-37 is an antiiinflammatory cytokine that inhibits IL-18 activity. https://t.co/IFQrOpBKdi
  10. Anakinra May Attenuate Stroke Outcomes 
  11. Precision Genetics Can Predict Methotrexate Non-Responders    
  12. 2 Weeks Off Methotrexate OK for Flu Vaccine   
  13. FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – FDA Panels Meet on Gout & OP (1.18.19)

Dr Jack Cush Reviews the news, articles and FDA Panel discussions from the past week

Assessing the Performance of Aging Physicians

A JAMA Viewpoint article examines the performance of aging surgeons and notes that the effects of aging affects physicians variably and that physician competency should be based on functional age (and abilities) rather than chronologic age. This argues against a mandatory retirement age for surgeons.

RheumNow Podcast – Gout Spot Light (1.11.19)

Dr. Jack Cush discusses the highlights from the past week on RheumNow.com:

RheumNow Podcast – A Grand New Year (1.4.19)

Dr. Jack Cush reviews the news and journals for the beginning of 2019. All from RheumNow.com. Best wishes for a charmed 2019! My advice: 1. Just show up. 2. If you can, then you must do. 3. Live each day as if it twas your 1st day/last day/make or break day. 4. Teach.

Best of 2018: U.S. News 2018-19 Rheumatology Rankings

The Annual U.S. News and World Report Rankings of Hospitals has listed the top contenders in the field of rheumatology. The U.S. News Review rates hospitals nationwide in 16 specialties – including rheumatology. Of the 4,500 hospitals covered by U.S. News that were analyzed, 158 were classified nationally in at least one specialty area.